-
1
المؤلفون: Tadashi Nakanishi, Yasutsuna Sasaki, Nobuaki Matsubara, Yoichi Naito, Namiki Masayuki, Ken Shimada, Hiroshi Obaishi, Hirofumi Mukai, Toshiaki Saeki
المصدر: Investigational New Drugs
مصطلحات موضوعية: Adult, Eribulin Mesylate, Combination therapy, Receptor, ErbB-2, Breast Neoplasms, Pharmacology, Antibodies, Monoclonal, Humanized, HER2 positive breast cancer, Loading dose, chemistry.chemical_compound, Trastuzumab, Phase I Studies, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, Pharmacology (medical), Furans, skin and connective tissue diseases, Aged, Taxane, business.industry, Eribulin mesylate, Stroke Volume, Ketones, Middle Aged, medicine.disease, Metastatic breast cancer, Japanese patients, Phase 1 study, Treatment Outcome, chemistry, Tolerability, Oncology, Female, business, Eribulin, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72484520f52b34938555da2b7569d205Test
-
2
المؤلفون: Minami Matsuda, Keishi Yamashita, Keisuke Miwa, Yasutsuna Sasaki, Namiki Masayuki, Ken Shimada, Kosei Hasegawa, Hiroo Ishida, Keiichi Fujiwara, Yutaka Takeuchi, Yasuhiro Fujiwara, Noriyuki Katsumata, Makoto Kodaira, Yu Sunakawa
المصدر: Investigational New Drugs
مصطلحات موضوعية: Monoclonal antibody, Adult, Male, medicine.medical_specialty, Metabolic Clearance Rate, Nausea, Antineoplastic Agents, Pharmacology, Antibodies, Monoclonal, Humanized, Gastroenterology, Folate receptor α, chemistry.chemical_compound, Asian People, Japan, Pharmacokinetics, Phase I Studies, Internal medicine, medicine, Humans, Folate Receptor 1, Pharmacology (medical), Adverse effect, Aged, Gastrointestinal Neoplasms, Ovarian Neoplasms, Dose-Response Relationship, Drug, business.industry, Farletuzumab, Cancer, Middle Aged, medicine.disease, Tolerability, chemistry, Oncology, Folate receptor, Area Under Curve, Phase I study, Female, medicine.symptom, Ovarian cancer, business, Half-Life
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41d554c0c911af7d7aa932653656aba8Test
-
3
المؤلفون: Helen X. Chen, David W. Cescon, Zhuo Chen, Sue Chow, Sebastien J. Hotte, Lillian L. Siu, Joanne Chiu, Ivan Diaz-Padilla, David S.P. Tan, Christian Kollmannsberger, Daniel J. Renouf, Meghan Perry, Hal W. Hirte, Elaine McWhirter, Philippe L. Bedard, David W. Hedley, Jeffrey A. Moscow
المصدر: Investigational New Drugs
مصطلحات موضوعية: 0301 basic medicine, Oncology, Adult, Male, medicine.medical_specialty, Temsirolimus, Combination therapy, Maximum Tolerated Dose, Recombinant Fusion Proteins, Phase 1, Pharmacology, 03 medical and health sciences, 0302 clinical medicine, Pharmacokinetics, Internal medicine, Phase I Studies, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, medicine, Mucositis, Edema, Humans, Pharmacology (medical), Adverse effect, Fatigue, AMG386, Aged, Sirolimus, business.industry, Middle Aged, medicine.disease, Rash, 3. Good health, Anorexia, 030104 developmental biology, Treatment Outcome, Tolerability, 030220 oncology & carcinogenesis, Female, medicine.symptom, business, Trebananib, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d054fd74a3577da7ba5f02e3e278453Test